Study of sRAGE, HMGB1, AGE, and S100A8/A9 Concentrations in Plasma and in Serum-Extracted Extracellular Vesicles of Pregnant Women With Preterm Premature Rupture of Membranes.

S100A8/A9 advanced glycation end products extracellular vesicles high-mobility group box 1 preterm premature rupture of membranes soluble receptor for advanced glycation end products

Journal

Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006

Informations de publication

Date de publication:
2020
Historique:
received: 20 02 2020
accepted: 15 05 2020
entrez: 14 7 2020
pubmed: 14 7 2020
medline: 14 7 2020
Statut: epublish

Résumé

Preterm premature rupture of membranes (PPROM), defined as rupture of fetal membranes prior to 37 weeks of gestation, complicates approximately 2-4% of pregnancies and is responsible for 40% of all spontaneous preterm births. PPROM arises from complex pathophysiological pathways with a key actor: inflammation. Sterile inflammation is a feature of senescence-associated fetal membrane maturity. During specific steps of sterile inflammation, cells also release highly inflammatory damage-associated molecular pattern markers (DAMPs), such as high-mobility group box 1 (HMGB1) or S100A8/A9, known to link and activate the receptor for advanced glycation end products (RAGE). The objective of this study was to measure longitudinally during pregnancy concentrations of the soluble form of RAGE (sRAGE) and its main ligands (AGE, HMGB1, S100A8/A9) in blood specimens. We studied 246 pregnant women (82 with PPROM and 164 matched control pregnant women without complications) from a cohort of 7,866 pregnant women recruited in the first trimester and followed during pregnancy until delivery. sRAGE, AGE, HMGB1, and S100A8/A9 concentrations were measured in plasma and in serum-extracted extracellular vesicles from first trimester (T1), second trimester (T2), and delivery (D). In plasma, we observed, in both PPROM and control groups, (i) a significant increase of HMGB1 concentrations between T1 vs. T2, T1 vs. D, but not between T2 vs. D; (ii) a significant decrease of sRAGE concentrations between T1 and T2 and a significant increase between T2 and D; (iii) a significant decrease of AGE from T1 to D; (iv) no significant variation of S100A8/A9 between trimesters. In intergroup comparisons (PPROM vs. control group), there were no significant differences in time variation taking into account the matching effects. There was a correlation between plasma and serum-extracted extracellular vesicle concentrations of sRAGE, AGE, HMGB1, and S100A8/A9. Our results suggest that the rupture of fetal membranes (physiological or premature) is accompanied by a variation in plasma concentrations of sRAGE, HMGB1, and AGE. The study of RAGE and its main ligands in extracellular vesicles did not give additional insight into the pathophysiological process conducting to PPROM.

Identifiants

pubmed: 32655405
doi: 10.3389/fphys.2020.00609
pmc: PMC7324632
doi:

Types de publication

Journal Article

Langues

eng

Pagination

609

Informations de copyright

Copyright © 2020 Bouvier, Giguère, Blanchon, Bujold, Pereira, Bernard, Gallot, Sapin and Forest.

Références

Ann N Y Acad Sci. 2008 Apr;1126:7-13
pubmed: 18448789
Cytokine. 2018 Aug;108:53-56
pubmed: 29571040
J Perinat Med. 2019 Apr 24;47(3):276-287
pubmed: 30412466
Aging (Albany NY). 2016 Feb;8(2):216-30
pubmed: 26851389
Clin Biochem. 2010 Mar;43(4-5):442-6
pubmed: 19909734
Am J Obstet Gynecol. 2000 Sep;183(3):738-45
pubmed: 10992202
J Clin Med. 2019 Nov 15;8(11):
pubmed: 31731659
J Matern Fetal Neonatal Med. 2015 Aug;28(12):1394-409
pubmed: 25190175
J Perinat Med. 2008;36(5):399-404
pubmed: 18771410
Clin Chem Lab Med. 2014 Aug;52(8):1169-78
pubmed: 24535301
Lancet. 1980 Jan 26;1(8161):192-4
pubmed: 6101643
Taiwan J Obstet Gynecol. 2018 Apr;57(2):211-216
pubmed: 29673663
Biol Reprod. 2016 Dec;95(6):130
pubmed: 27806943
Semin Perinatol. 2017 Nov;41(7):409-419
pubmed: 28807394
J Reprod Immunol. 2017 Sep;123:3-11
pubmed: 28858636
PLoS One. 2017 Mar 9;12(3):e0173312
pubmed: 28278303
Inflamm Res. 2016 Feb;65(2):95-102
pubmed: 26603731
J Matern Fetal Neonatal Med. 2012 Sep;25(9):1762-8
pubmed: 22339587
J Matern Fetal Neonatal Med. 2019 Dec;32(24):4102-4107
pubmed: 29804482
Am J Obstet Gynecol. 2018 Nov;219(5):478.e1-478.e21
pubmed: 30138617
Biomed Res Int. 2015;2015:568042
pubmed: 26413536
PLoS Biol. 2008 Dec 2;6(12):2853-68
pubmed: 19053174
J Reprod Immunol. 2012 Mar;93(2):69-74
pubmed: 22382005
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Am J Reprod Immunol. 2016 Jan;75(1):3-7
pubmed: 26781934
Pharmacol Ther. 2016 Nov;167:120-131
pubmed: 27492899
J Matern Fetal Neonatal Med. 2019 Aug;32(16):2758-2762
pubmed: 29506420
Biomed Res Int. 2016;2016:2719460
pubmed: 27556030
Endocrinology. 2019 Mar 1;160(3):639-650
pubmed: 30668697

Auteurs

Damien Bouvier (D)

Biochemistry and Molecular Genetic Department, Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France.
Faculty of Medicine, CNRS 6293, INSERM 1103, GReD, Université Clermont Auvergne, Clermont-Ferrand, France.

Yves Giguère (Y)

Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Québec City, QC, Canada.
Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec City, QC, Canada.

Loïc Blanchon (L)

Faculty of Medicine, CNRS 6293, INSERM 1103, GReD, Université Clermont Auvergne, Clermont-Ferrand, France.

Emmanuel Bujold (E)

Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Québec City, QC, Canada.
Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval, Québec City, QC, Canada.

Bruno Pereira (B)

Biostatistics Unit Direction de la Recherche Clinique et des Innovations (DRCI), Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France.

Nathalie Bernard (N)

Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Québec City, QC, Canada.

Denis Gallot (D)

Faculty of Medicine, CNRS 6293, INSERM 1103, GReD, Université Clermont Auvergne, Clermont-Ferrand, France.
Department of Obstetrics and Gynecology, Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France.

Vincent Sapin (V)

Biochemistry and Molecular Genetic Department, Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France.
Faculty of Medicine, CNRS 6293, INSERM 1103, GReD, Université Clermont Auvergne, Clermont-Ferrand, France.

Jean-Claude Forest (JC)

Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Québec City, QC, Canada.
Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec City, QC, Canada.

Classifications MeSH